Phosphodiesterase 4 Inhibitors

Warning

APREMILAST

Administration: Oral

Dose:

  • The recommended dose of APREMILAST is 30mg twice daily taken orally, morning and evening, approximately 12 hours apart, swallowed whole, with no food restrictions.
  • To reduce risk of GI symptoms an initial titration over 5 days from 10mg daily on day 1 to 30mg twice daily on day 6 is recommended:
    • Day 1: 10 mg in morning.
    • Day 2: 10 mg in morning and 10 mg in evening.
    • Day 3: 10 mg in morning and 20 mg in evening.
    • Day 4: 20 mg in morning and 20 mg in evening.
    • Day 5: 20 mg in morning and 30 mg in evening.
    • Day 6 and thereafter: 30 mg twice daily.
  • Dosage in Severe Renal Impairment:
    • Recommended dose is 30 mg once daily.
    • For initial dosage titration, titrate using only morning schedule and skip afternoon doses.

Time to response: 8 weeks to 6 months

Indications: Psoriatic Arthritis.

Contraindications:

  • Hypersensitivity to APREMILAST or any excipients in formulation.
  • Patients with rare hereditary problems of galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption.
  • Pregnancy and breastfeeding.
  • History of suicidal ideation/behaviour.

Monitoring: No blood monitoring is required.

Ensure:

  • Adequate contraception whilst taking APREMILAST and for 3 days after stopping it.
  • Use with strong cytochrome p450 enzyme inducers (e.g. RIFAMPICIN, PHENOBARBITAL, CARBAMAZEPINE, PHENYTOIN, St. John’s Wort) is not recommended because loss of efficacy may occur.

In the event of:

  • Side effects such as diarrhoea, headache, nausea and upper respiratory tract infections are common in the first 2 weeks of treatment and tend to resolve over time with continued dosing. Initial reassurance is all that is required.
  • Worsening or new psychiatric symptoms - stop APREMILAST.
  • 5-10% weight loss – consider stopping drug particularly in those with low BMI.

Editorial Information

Last reviewed: 16/11/2021

Next review date: 16/11/2024

Author(s): Dr Karen Donaldson (lead author), Dr Elizabeth Murphy, Professor Robin Munro, Dr Sanjiv Nandwani, Dr Saira Batool, Dr Georgiana Young, (other contributors to documents included in guideline).

Version: V1

Approved By: Dr Karen Donaldson Rheumatology Clinical Lead; Rheumatology Consultants

Reviewer name(s): Karen Donaldson.